fact-sheet
The FDA and the ICH S7B provide guidelines for assessing cardiac safety. In Vitro Assays are the key strategies in cardiac safety evaluation. These assays involve the use of cell lines or isolated hearts to assess the direct effects of drugs on cardiac ion channels, particularly the hERG channel, which is associated with the QT interval prolongation.
The Comprehensive In Vitro Proarrhythmia Assay (CIPA) is an example of a modernized screening paradigm that assesses multiple ion channels and cardiomyocyte function. Manual patch clamp is the gold standard for ion channel detection methods.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.